150727-73-4

Upstream product

• 329924-27-8 4,6-dichloro-5-(2-methoxyphenoxy)-2-cyclopropyl-pyrimidine 

Downstream Products

• 329924-39-2 N-[6-(2-amino-ethoxy)-2-cyclopropyl-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide 
• 150726-47-9 4-tert-butyl-N-[2-cyclopropyl-6-(2-hydroxy-ethoxy)-5-(2-methoxyphenoxy)-pyrimidin-4-yl]-benzenesulfonamide 
• 329925-15-7 N-[6-(3-amino-propoxy)-2-cyclopropyl-5-(2-methoxy-phenoxy)-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide 

Relevant academic research and scientific papers

Bis-sulfonamides as endothelin receptor antagonists

Modification of the structure of bosentan 1, the first marketed endothelin receptor antagonist (Tracleer), by introduction of a second sulfonamide function at the alkoxy side chain, led to bis-sulfonamides 2. This allowed to prepare dual ETA/ETB as well as ETB receptor selective antagonists, which could serve as tools to investigate the pharmacological consequences of selective ETB receptor blockade.

SULFONAMIDES

The novel sulfonamides of formula I, STR1 in which the symbols R. sup.1-R 9, R a, R b, X, Y and n have the significance given in the description and salts thereof can be used for the treatment of circulatory disorders, especially hypertension, ischemia, vasopasms and angina pectoris.